Crescent Biopharma Stock Forecast
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:49 AM ET
CBIO analyst consensus
Consensus (8 analysts)
strong_buy
Avg. price target
$31.50+136.75%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Crescent Biopharma (2026-10-08), 8 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $31.50, with a high estimate of $36.00 and a low estimate of $27.00. The average target implies upside of 136.8% from the current price of $13.31.
The spread between the highest and lowest targets is 33.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CBIO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 13% |
| Buy | 7 | 88% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $27.00 | +102.93% |
| Average target | $31.50 | +136.75% |
| High target | $36.00 | +170.57% |